Abstract Submission
The symposium endeavors to foster valuable collaboration among peers from across the globe and delve into pioneering research across all facets of radiopharmaceutical science. This encompasses synthesis, in vitro and ex vivo studies, in vivo biodistribution or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of novel targeted radiotracers. Program development is under the expert guidance of internationally renowned leaders in the field and will be almost completely developed based on the peer-reviewed abstract submissions.
Key Dates
Abstract Submission Opens: September 2, 2026
Abstract Submission Deadline: December 1, 2026
Abstract Submission Categories & Descriptions
1. Carbon-11 and Fluorine-18 Radiochemistry
This category welcomes scientific contributions related to the development and utility of Carbon-11 and Fluorine-18 radiochemistry advancements. Topics may include the design and radiosynthesis of 11C- and 18F-labelled radiotracers, reagents, and synthons and the development of novel Carbon-11 and Fluorine-18 radiosynthetic methods and strategies, as well as bioconjugation strategies or similar concepts within the 18F chemistry domain.
2. Radiometal & Chelator Chemistry
This category welcomes scientific contributions that cover the broad domains of radiometal ion complexation chemistry, ligand design, synthesis, and characterization, as well as the development or application of state-of-the-art bioconjugation methods involving radiometals.
3. Chemistry of Other Radioisotopes
This category welcomes scientific contributions that cover chemistry related to radioisotopes other than 11C, 18F, and radiometals. Topics may include the design and synthesis of radiotracers or radiolabeled synthons as well as development or application of bioconjugation methods.
4. Radionuclide Therapy and Theranostics
This category welcomes scientific contributions that cover the preparation, characterization, and in vitro and in vivo evaluation of radionuclides and radiolabeled compounds for the treatment or for the combined diagnosis and treatment of the spectrum of different diseases including preclinical and clinical studies. This category welcomes scientific contributions in radiotherapy and in contributions that cover the integration of diagnosis and treatment to predict response or improve treatment effectiveness, such as image-guided therapies, in combination with radiotherapy, chemotherapy, and immunotherapy.
5. Multimodality Imaging Probes or Techniques
This category welcomes scientific contributions that cover design, chemistry, labeling strategies, and applications of multimodal imaging probes. This includes approaches to implement multimodality imaging techniques: e.g. monomolecular probe, sequential or cocktail injection of biomarkers, and combining two or more imaging modalities (PET/SPECT, optical imaging, MRI and ultrasound, etc.)
6. Nanomedicines and New Biological Vectors
This category welcomes scientific contributions related to the development and application of radiolabeled nanomaterials and natural or engineered biological vectors. This includes the design, synthesis, labeling strategies, and preclinical or early clinical application of nanomedicines and biological vectors.
7. Imaging Applications of Radiolabeled Compounds in Oncology
This category welcomes scientific contributions that cover In vitro and in vivo experimental evaluation of new radiolabeled compounds for imaging tumors including preliminary clinical studies and basic research on novel diagnostic applications in oncology using known labeled compounds.
8. Applications of Radiolabeled Compounds in Neuroscience
This category welcomes scientific contributions that cover in vitro and in vivo experimental evaluation of new radiolabeled compounds for imaging brain chemistry and function including preliminary clinical studies and basic research on novel diagnostic applications in Neurology using known labeled compounds.
9. Applications of Radiolabeled Compounds in Other Fields
This category welcomes scientific contributions that cover in vitro and in vivo experimental evaluation of new radiolabeled compounds for imaging other than neurologic and oncologic applications, such as agents for cardiovascular, infection, inflammation, etc. Preliminary clinical studies and basic research on novel diagnostic applications in these fields using known labeled compounds fall into this category.
10. First-in-human Studies
This category welcomes scientific contributions that report first-in-human clinical studies of new radiopharmaceutical candidates in all diagnostic applications.
11. Radiopharmaceutical Technologies
This category welcomes scientific contributions related to all the technological innovations that support the translation of basic radiochemical discoveries into practice. This includes advancements in Automation, Microfluidics, Process Development, Green Radiochemistry, and similarly related strategies and customizations.
12. Radiopharmacy
This category welcomes scientific contributions related to radiosynthesis optimization of known radiotracers, adaptation of radiosynthetic methods to regulatory compliance for patient use, their good manufacturing production, improvement in radioanalytical methods and compounding of radiopharmaceuticals for routine clinical use, and related topics.
13. Targetry
This category welcomes scientific contributions related to cyclotron, reactor or linac isotope production, targetry, and purification chemistry.
14. Artificial Intelligence and Computational Chemistry
This category welcomes scientific contributions related to all aspects of computational chemistry to calculate or support radiotracer design and development. Artificial intelligence applications in radiochemistry involving big data and machine learning tools for detection of molecular properties (e.g. pharmacophores), predictive analysis (e.g. molecular docking), as well as design and discovery of radiotracers and targets fall into this category
Questions?
Contact Elaine Murray, Associate Executive Director emurray@srsweb.org
Submission Guidelines
(Also found in the submission system)
Your abstract body must not exceed 500 words; this includes any words used in a table as part of the abstract body. Only one JPG figure may be uploaded, but you can combine up to three images into one file.
Organizers strongly encourage you to divide your abstract as follows:
• Objectives
• Methods
• Results
• Conclusions
• References (if word count permits)
• Acknowledgments (if applicable)
In order to deliver the best submission, some suggestions on what to include in each section are given below:
• Objectives: Describe your topic, field of application, biological target, previous works, limitations; be aware that iSRS2027 prefers works that have not been accepted for publication before the submission deadline.
• Methods: Give a brief experimental description, identifying new compounds or drawing their structures.
• Results: Give us data! You can do it by adding them in a table or figure.
• Conclusions: Summarize key result achieved, noting difference/novelty/advancement with current literature or previous works from the same group, and overall impact.
If you want to view an abstract example, download Guidelines and Example Abstracts for Authors.
You are also strongly encouraged to follow the nomenclature guidelines (DOI: 10.1016/j.nucmedbio.2017.09.004) and rules for radiochemical conversion (DOI: 10.1016/j.nucmedbio.2020.11.003) recently published by an international working group.
You will be able to add co-authors to the Abstract once you click “Submit.” When adding co-authors who are already in the database system, you cannot modify their affiliation or any of their profile data - the co-author must modify their own data. They can do this by visiting the profile home.